iShares Global Tech ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares Global Tech ETF trades at $149.84 (market cap $10.03B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.5× iShares Global Tech ETF's market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| IXN | ROIV | |
|---|---|---|
Market Cap | $10.03B | $24.72B |
Volume | 286,617 | 6,279,442 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $41.81 |
52-Week Low | $95.76 | $16.04 |
Typical Hold Time | 47 Days | 1 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
IXN, the iShares Global Tech ETF, trades at $149.84, down 1.52% on the day but near its 52-week high of $151.40, indicating strong momentum. Technical signals are bullish overall, with moving averages supporting an uptrend, while oscillators remain neutral. Recent news highlights the ETF hitting new highs and trading at a high-teens P/E with a compelling long-term EPS growth outlook, though concentration and AI exposure pose risks.
The outlook for IXN is positive, driven by global tech diversification and AI growth opportunities, but investors face risks from portfolio concentration and market volatility. Wall Street sentiment is bullish, with analysts citing valuation compression and earnings potential as key catalysts for further gains.
No Aura AI signal available yet.
Trailing returns across standard periods
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →